NEW YORK, Aug 10 (Reuters) - Hims & Hers Health on Monday posted second-quarter revenue above ‌estimates and raised its annual revenue ‌forecast, as the telehealth company benefited from an increase ​in subscribers and expanding its personalized healthcare offerings. The company's pivot to FDA-approved treatments such as Novo Nordisk's Wegovy helped drive engagement and traffic ‌across its platform. In ⁠May, Hims said it would pivot to offering branded weight-loss drugs, moving ⁠away from lower-cost compounded GLP-1 treatments that had helped drive growth to branded versions. Hims reported revenue of $753 million during ‌the quarter, compared with $544 ​million a year ago. The company raised its ​full-year revenue ​guidance to a range of $3.1 billion to $3.3 billion from its previous range of 2.8 ​billion to $3 ‌billion.